Sopherion Therapeutic Inc is categorized under Commercial Biotechnical Research in Princeton, NJ and active since 2000.
Sopherion Therapeutic Inc was established in 2000, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Ronald Goldfarb at the company’s single location by writing to 104 Carnegie Center # 200, Princeton, New Jersey NJ 08540 or by phoning (609) 986-2021. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Sopherion Therapeutic Inc |
| Contact Person: | Ronald Goldfarb |
| Address: | 104 Carnegie Center # 200, Princeton, New Jersey 08540 |
| Phone Number: | (609) 986-2021 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2000 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Sopherion Therapeutic Inc was started in 2000 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Ronald Goldfarb for inquiries that concern Sopherion Therapeutic Inc by calling the company number (609) 986-2021, as your correspondence is most welcome. Additionally, the physical location of the single location of Sopherion Therapeutic Inc can be found at the coordinates 40.323214,-74.644894 as well as the street address 104 Carnegie Center # 200 in Princeton, New Jersey 08540.
For its online presence, you may visit Sopherion Therapeutic Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.